var data={"title":"Noninsulinoma pancreatogenous hypoglycemia syndrome","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Noninsulinoma pancreatogenous hypoglycemia syndrome</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/contributors\" class=\"contributor contributor_credentials\">F John Service, MD, PhD</a></dd><dd><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/contributors\" class=\"contributor contributor_credentials\">Adrian Vella, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/contributors\" class=\"contributor contributor_credentials\">Irl B Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/contributors\" class=\"contributor contributor_credentials\">Jean E Mulder, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 24, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) identifies a group of hyperinsulinemic hypoglycemic patients with unique clinical, diagnostic, surgical, and pathologic features [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,2\" class=\"abstract_t\">1,2</a>]. These patients experience predominantly postprandial hypoglycemia and have nesidioblastosis with islet cell hypertrophy, findings different from those in patients with insulinomas.</p><p>The clinical manifestations, pathological findings, diagnosis, and treatment of NIPHS will be reviewed here. Other causes of hypoglycemia and how to differentiate among these causes are reviewed elsewhere. (See <a href=\"topic.htm?path=hypoglycemia-in-adults-clinical-manifestations-definition-and-causes\" class=\"medical medical_review\">&quot;Hypoglycemia in adults: Clinical manifestations, definition, and causes&quot;</a> and <a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach\" class=\"medical medical_review\">&quot;Hypoglycemia in adults without diabetes mellitus: Diagnostic approach&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">DEFINITION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is a rare syndrome characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an insulinoma. Pancreatic specimens from such patients show beta cell hypertrophy, islets with enlarged and hyperchromatic nuclei, and increased islets budding from periductular epithelium [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1-3\" class=\"abstract_t\">1-3</a>]. These histologic findings are characteristic of nesidioblastosis, a term that refers to neoformation of islets of Langerhans from pancreatic duct epithelium [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/4\" class=\"abstract_t\">4</a>]. The pathologic findings are similar to those seen in neonates and infants with persistent hyperinsulinemic hypoglycemia. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-persistent-hyperinsulinemic-hypoglycemia-of-infancy#H10\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy&quot;, section on 'Pathology of the beta cell'</a>.)</p><p>Formal epidemiologic studies have not been conducted for NIPHS; however, the condition appears to be rarer than insulinoma. For example, during the period from 1996 to 2004, 20 patients with NIPHS (16 male, 4 female) and 118 patients with insulinoma (51 male, 67 female) were surgically confirmed at the Mayo Clinic [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,2,5\" class=\"abstract_t\">1,2,5</a>].</p><p>Although the underlying pathologic features of NIPHS and post-gastric bypass hypoglycemia are similar in most instances, post-gastric bypass hypoglycemia is considered a separate clinical entity. (See <a href=\"#H5855587\" class=\"local\">'Nesidioblastosis after Roux-en-Y gastric bypass surgery'</a> below.)</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">CLINICAL FEATURES</span></p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The predominant clinical feature of noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is postprandial hypoglycemia. In a series of 18 patients from the Mayo Clinic, age range 16 to 78 years old, mean body mass index (BMI) 25.7 <span class=\"nowrap\">kg/m<sup>2</sup>,</span> with a male predominance (70 percent), symptoms occurred postprandially, two to four hours after meals, and only rarely while fasting [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,2,6\" class=\"abstract_t\">1,2,6</a>]. All patients had neuroglycopenic symptoms, and several lost consciousness or had generalized seizures. Forty percent of the patients had a history of upper gastrointestinal surgery (not gastric bypass) [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. In smaller series and case reports, a similar preponderance of postprandial hypoglycemia, neuroglycopenic symptoms, and male predominance was noted [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/7-14\" class=\"abstract_t\">7-14</a>]. However, fasting hypoglycemia has also been reported [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/13,15,16\" class=\"abstract_t\">13,15,16</a>].</p><p>In contrast, most patients with insulinomas have fasting hypoglycemia. Though they may occasionally also have postprandial symptoms, the occurrence of symptoms solely postprandially is rare (approximately 5 percent of patients). (See <a href=\"topic.htm?path=insulinoma#H2\" class=\"medical medical_review\">&quot;Insulinoma&quot;, section on 'Clinical features'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Biochemical findings</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>During episodes of hypoglycemia, patients with NIPHS have biochemical findings similar to those of insulinoma, including elevated plasma insulin, C-peptide, and proinsulin concentrations; low plasma beta-hydroxybutyrate; and a negative <span class=\"nowrap\">sulfonylurea/meglitinide</span> screen (<a href=\"image.htm?imageKey=ENDO%2F56314\" class=\"graphic graphic_table graphicRef56314 \">table 1</a>).</p><p class=\"headingAnchor\" id=\"H20267827\"><span class=\"h2\">Histopathology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathology descriptions of excised pancreatic tissue include islet cell hypertrophy with enlarged and hyperchromatic nuclei, sometimes islet cell hyperplasia, and increased periductular islets [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,3,8\" class=\"abstract_t\">1,3,8</a>]. Islet-like cells budding off exocrine ducts have been noted and were most evident on immunohistochemical staining for chromogranin A (<a href=\"image.htm?imageKey=ENDO%2F51119\" class=\"graphic graphic_picture graphicRef51119 \">picture 1</a>) [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. The hypertrophic islet cells also stained positively for insulin, glucagon, somatostatin, and pancreatic polypeptide [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,9\" class=\"abstract_t\">1,9</a>]. The distribution of the hormones within the islets was normal, with between 60 to 80 percent of the islet cells staining for insulin. Many of the cells budding off ducts also contained insulin.</p><p>This constellation of pathologic changes is referred to as nesidioblastosis, a form of primary islet cell hypertrophy and neodifferentiation of islet of Langerhans cells from pancreatic duct epithelium [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/3\" class=\"abstract_t\">3</a>]. Nesidioblastosis has been associated with persistent hyperinsulinemic hypoglycemia in infants [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/4,17,18\" class=\"abstract_t\">4,17,18</a>] and less often in adults [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/3,19-25\" class=\"abstract_t\">3,19-25</a>]. These pathologic findings have also been described in nontumor pancreatic tissue of patients with insulinomas [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/26,27\" class=\"abstract_t\">26,27</a>]; in patients previously treated with insulin [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/22,28\" class=\"abstract_t\">22,28</a>] or a sulfonylurea [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/29\" class=\"abstract_t\">29</a>]; and in patients with other islet cell tumors, such as gastrinomas [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/30\" class=\"abstract_t\">30</a>] or multiple endocrine neoplasia type 1 [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/31\" class=\"abstract_t\">31</a>]. (See <a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-persistent-hyperinsulinemic-hypoglycemia-of-infancy\" class=\"medical medical_review\">&quot;Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy&quot;</a> and <a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach#H18\" class=\"medical medical_review\">&quot;Hypoglycemia in adults without diabetes mellitus: Diagnostic approach&quot;, section on 'Determining the cause of hypoglycemia'</a>.)</p><p>These pathologic findings probably correlate with the clinical features of the syndrome of hyperinsulinemic hypoglycemia. However, it should be noted that subtle histologic changes characteristic of nesidioblastosis have been observed in 36 percent of patients in an autopsy series of 207 patients with no history of hypoglycemia [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/32\" class=\"abstract_t\">32</a>]. Some have proposed that the morphologic features of nesidioblastosis may be a variant of normal rather than the anatomic basis for hypoglycemia in adults with hyperinsulinism [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Nevertheless, analogous to nonfunctioning insulinomas, there may be nonfunctional nesidioblastosis to account for its finding in nonhypoglycemic persons.</p><p>In an analysis of pancreatic tissue from 36 cases (27 post-gastric bypass) of nesidioblastosis, increased insulin-like growth factor-2, insulin-like growth factor-1 receptor alpha, and transforming growth factor receptor beta 3 expression were noted in the islets of patients compared with controls who had benign exocrine pancreatic tumors [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. These findings suggest a role for growth factors in the pathogenesis of nesidioblastosis in adults.</p><p class=\"headingAnchor\" id=\"H5855575\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In adults, hypoglycemia due to endogenous hyperinsulinism, with negative screens for <span class=\"nowrap\">sulfonylurea/meglitinide</span> and insulin antibodies, can be caused by:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A beta cell tumor (eg, insulinoma)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A functional beta cell disorder (eg, nesidioblastosis) due to either noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) or post-gastric bypass hypoglycemia</p><p/><p class=\"headingAnchor\" id=\"H5855581\"><span class=\"h2\">Insulinoma</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>It is usually not difficult to distinguish insulinoma from NIPHS, considering the timing of symptoms (typically fasting for insulinoma and postprandial for NIPHS), gender preference (male predominance), and, ultimately, the results of localization studies. Overall, with appropriate preoperative localization studies plus intraoperative ultrasonography and palpation, a tumor (or tumors) can be identified in 98 percent of patients with insulinomas. (See <a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">&quot;Insulinoma&quot;</a>.)</p><p>A 72-hour fast should not be performed to differentiate insulinoma from NIPHS, because of potential overlap in responses; rare cases of insulinoma may have negative fasts [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/34\" class=\"abstract_t\">34</a>] and rare cases of NIPHS may have positive fasts [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/8,15,19,35\" class=\"abstract_t\">8,15,19,35</a>]. Thus, the hypoglycemic response to a 72-hour fast cannot definitively distinguish NIPHS from insulinoma. (See <a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach#H9\" class=\"medical medical_review\">&quot;Hypoglycemia in adults without diabetes mellitus: Diagnostic approach&quot;, section on '72-hour fast'</a>.)</p><p class=\"headingAnchor\" id=\"H5855587\"><span class=\"h2\">Nesidioblastosis after Roux-en-Y gastric bypass surgery</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Although endogenous hyperinsulinemic hypoglycemia is rare, there have been several reports of it occurring after Roux-en-Y gastric bypass (RYGB) surgery [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/36-39\" class=\"abstract_t\">36-39</a>]. In the initial series, six patients were described with symptomatic postprandial hypoglycemia (symptoms of confusion, tunnel vision, and loss of consciousness occurring one to three hours after eating) six months to eight years following RYGB [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/36\" class=\"abstract_t\">36</a>]. Five of these patients had evidence of islet cell hyperplasia (nesidioblastosis) and one had both nesidioblastosis and evidence of a multifocal insulinoma. In a subsequent report, 36 patients who underwent partial pancreatectomy for nesidioblastosis at Mayo Clinic between 1994 and 2007 were evaluated [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/6\" class=\"abstract_t\">6</a>]. Twenty-seven of the patients had previously undergone RYGB. The time from RYGB to pancreatic resection was on average 54 months. In contrast to patients with NIPHS, there was a female predominance (92 percent). Patients with severe postprandial hypoglycemia and pancreatic islet hyperplasia after RYGB have also been reported from other institutions [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/37-39\" class=\"abstract_t\">37-39</a>].</p><p>Although nesidioblastosis following RYGB and NIPHS have some features in common (eg, postprandial hyperinsulinemic hypoglycemia, negative radiologic localization but positive calcium stimulation test, and histologic findings of nesidioblastosis), they appear to be distinct diseases:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>NIPHS is much less common than post-gastric bypass hypoglycemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with NIPHS have never undergone gastric bypass and they are predominantly male, as opposed to the female predominance for post-gastric bypass hypoglycemia.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with NIPHS never have insulinoma and virtually never have fasting hypoglycemia, both of which may be observed rarely in post-gastric bypass hypoglycemia [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p>Several hypotheses have been proposed for the etiology of islet cell hyperplasia following RYGB surgery: hormonal changes (possibly involving insulin-stimulating glucagon-like peptide-1 [GLP-1], glucose-dependent insulinotropic polypeptide [GIP], or ghrelin), unidentified factors from the proximal intestine, or disruption in the presurgery homeostasis of insulin resistance and hyperinsulinemia with rapid weight loss [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/36,37,41-44\" class=\"abstract_t\">36,37,41-44</a>]. After reversal of gastric bypass, hypoglycemia persisted in some case reports [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/37,45\" class=\"abstract_t\">37,45</a>] but improved in others [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/46-48\" class=\"abstract_t\">46-48</a>].</p><p class=\"headingAnchor\" id=\"H666059\"><span class=\"h3\">Dumping syndrome</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Dumping syndrome, which can occur after gastric bypass surgery, particularly when high levels of simple carbohydrates are ingested, is characterized by postprandial diaphoresis, weakness, dizziness, and palpitations due to intravascular volume contraction and not hypoglycemia. In patients with dumping syndrome, symptoms occur within 15 to 30 minutes of a meal. In contrast, symptoms due to post-gastric bypass hypoglycemia occur two to three hours after a meal, and the plasma glucose is low when the symptoms are present. (See <a href=\"topic.htm?path=postprandial-reactive-hypoglycemia#H8\" class=\"medical medical_review\">&quot;Postprandial (reactive) hypoglycemia&quot;, section on 'Alimentary hypoglycemia'</a>.)</p><p class=\"headingAnchor\" id=\"H20268413\"><span class=\"h1\">DIAGNOSTIC EVALUATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnostic approach to hypoglycemia is reviewed briefly below and in more detail separately. Findings on pathology ultimately confirm the presence of nesidioblastosis, which is the typical finding in patients with noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) and is only rarely described as a concomitant finding in patients with insulinoma [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/26,27\" class=\"abstract_t\">26,27</a>]. (See <a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach#H3\" class=\"medical medical_review\">&quot;Hypoglycemia in adults without diabetes mellitus: Diagnostic approach&quot;, section on 'Approach to testing'</a>.)</p><p class=\"headingAnchor\" id=\"H1423373789\"><span class=\"h2\">Laboratory evaluation</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The initial evaluation of hypoglycemia includes measurement of glucose, insulin, proinsulin, C-peptide, beta-hydroxybutyrate, and <span class=\"nowrap\">sulfonylurea/meglitinide</span> screening during an episode of hypoglycemia (<a href=\"image.htm?imageKey=ENDO%2F56314\" class=\"graphic graphic_table graphicRef56314 \">table 1</a>).</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with endogenous hyperinsulinism, insulin antibodies should be measured to distinguish insulin autoimmune hypoglycemia from other causes of hyperinsulinism. Insulin antibodies do not need to be drawn during hypoglycemia.</p><p/><p class=\"headingAnchor\" id=\"H5854725\"><span class=\"h2\">Localization studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In patients with endogenous hyperinsulinemic hypoglycemia (and negative screens for <span class=\"nowrap\">sulfonylurea/meglitinide</span> and insulin antibodies), localization studies are necessary to distinguish between the presence of an insulinoma versus a diffuse process (islet cell <span class=\"nowrap\">hyperplasia/nesidioblastosis)</span>. The choice of localization procedure depends upon which tests are available and local radiologic skill. Transabdominal ultrasonography is our preferred initial test for the identification of an insulinoma. (See <a href=\"topic.htm?path=insulinoma#H13\" class=\"medical medical_review\">&quot;Insulinoma&quot;, section on 'Tumor localization'</a>.)</p><p>Several noninvasive procedures are available, including computed tomography (CT), magnetic resonance imaging (MRI), transabdominal ultrasonography, 111-In-pentetreotide imaging, and fluorine-18-L-dihydroxyphenylalanine positron emission tomography (18F-DOPA PET). Radiological localization studies are negative for insulinoma in patients with NIPHS. In the Mayo series, as an example, all radiologic studies (transabdominal ultrasonography, triple phase CT, celiac axis angiography, and intraoperative ultrasonography) were negative for insulinoma [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. The sensitivity of each of these preoperative studies is only approximately 50 to 60 percent, but their combined sensitivity is significantly higher.</p><p>In patients with complex cases of endogenous hyperinsulinemic hypoglycemia and negative radiologic localization studies, a selective arterial calcium stimulation test (SACST) with hepatic venous sampling should be performed to establish that the hyperinsulinemia has a pancreatic origin and, in addition, its regionality within the pancreas. This procedure is important to perform in cases where pancreatic exploration is considered, and it should be conducted by an interventional radiologist skilled in cannulating intraabdominal vessels. The patient may have to be referred to a tertiary center.</p><p>A SACST involves injections of <a href=\"topic.htm?path=calcium-gluconate-drug-information\" class=\"drug drug_general\">calcium gluconate</a>, an insulin secretagogue, into arteries supplying the pancreas with subsequent sampling of the right hepatic venous effluent for insulin [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/49,50\" class=\"abstract_t\">49,50</a>]. A positive result is defined as a doubling or tripling of the basal hepatic venous serum insulin concentration. The increase in insulin occurs in samples from the artery supplying the region with hyperfunctioning islets, either an insulinoma or islet hypertrophy, which facilitates operative localization.</p><p>In patients with NIPHS, positive responses are usually observed after injection of multiple arteries, in contrast to insulinoma where the response is positive in one artery alone, unless the tumor resides in an area fed by two arteries or the patient has multiple insulinomas scattered throughout the pancreas [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1\" class=\"abstract_t\">1</a>]. Thus, focal versus diffuse positivity does not provide incontrovertible evidence for or against <span class=\"nowrap\">insulinoma/nesidioblastosis,</span> since insulinoma may be multiple and nesidioblastosis may be concentrated in one portion of the pancreas. (See <a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach#H24\" class=\"medical medical_review\">&quot;Hypoglycemia in adults without diabetes mellitus: Diagnostic approach&quot;, section on 'Arterial calcium stimulation'</a> and <a href=\"topic.htm?path=insulinoma#H13\" class=\"medical medical_review\">&quot;Insulinoma&quot;, section on 'Tumor localization'</a> and <a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">&quot;Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Mild to moderate symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with mild to moderate symptoms, nutritional modification is a reasonable initial intervention. Nutritional modification, particularly reduction of free carbohydrate intake and spacing carbohydrate intake evenly throughout the day, has been reported to reduce postprandial glycemic excursions and mild symptoms of hypoglycemia in some patients with post-bypass postprandial hypoglycemia [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/38,51\" class=\"abstract_t\">38,51</a>].</p><p>For patients with noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS), similar nutritional modification may be helpful. If mild to moderate symptoms persist, we prescribe the alpha-glucosidase inhibitor <a href=\"topic.htm?path=acarbose-drug-information\" class=\"drug drug_general\">acarbose</a> (initial dose 25 mg three times daily, with each main meal).</p><p>In case reports, <a href=\"topic.htm?path=octreotide-drug-information\" class=\"drug drug_general\">octreotide</a>, <a href=\"topic.htm?path=verapamil-drug-information\" class=\"drug drug_general\">verapamil</a>, <a href=\"topic.htm?path=diazoxide-drug-information\" class=\"drug drug_general\">diazoxide</a>, and <a href=\"topic.htm?path=acarbose-drug-information\" class=\"drug drug_general\">acarbose</a> have reportedly improved hypoglycemic symptoms in patients with post-gastric bypass hypoglycemia or, in fewer reports, NIPHS [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/38,52-55\" class=\"abstract_t\">38,52-55</a>]. The evaluation of the post-gastric bypass patients did not always include careful documentation of postprandial hyperinsulinemic hypoglycemia, and therefore, the diagnosis of hypoglycemia due to nesidioblastosis is uncertain in some of these cases. Nevertheless, in patients with NIPHS and mild to moderate symptoms refractory to a low carbohydrate diet, we believe it is worthwhile to try a course of acarbose, starting at a low dose and advancing to the point of balance between tolerance and benefit, not to exceed 100 mg three <span class=\"nowrap\">times/day</span>. Success with this approach avoids surgery.</p><p class=\"headingAnchor\" id=\"H335477\"><span class=\"h2\">Severe or refractory symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>For patients with NIPHS and severe postprandial hypoglycemia (eg, neuroglycopenia with loss of consciousness) or with symptoms refractory to medical management, surgery is the mainstay of therapy. In case series and reports, partial or subtotal pancreatectomy successfully relieved hypoglycemic symptoms in the majority of patients with NIPHS and post-gastric bypass nesidioblastosis [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1,2,13,24,25,36,37,39,56\" class=\"abstract_t\">1,2,13,24,25,36,37,39,56</a>].</p><p>The degree of surgery is determined by the results of the selective arterial calcium stimulation test (SACST). The pancreas to the left of the superior mesenteric vein is resected when the SACST is positive only after splenic artery injection, and the resection is extended to the right of the superior mesenteric vein when the test is positive after injection of an additional artery. The pancreas can be debulked in a gradient-guided fashion, even in patients whose disease appears to involve the whole pancreas.</p><p>For post-gastric bypass patients with severe hypoglycemia due to nesidioblastosis, reversal of gastric bypass has been suggested as an alternative to pancreatectomy. After reversal, hypoglycemia persisted in some case reports [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/37,45\" class=\"abstract_t\">37,45</a>] but improved in others [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/46-48\" class=\"abstract_t\">46-48</a>]. In our experience, conversion of the Roux-en-Y gastric bypass (RYGB) to sleeve gastrectomy is the current procedure of choice. However, if there is no improvement, partial pancreatectomy may still be necessary. For the patient with post-gastric bypass hypoglycemia from insulinoma, surgery is the preferred treatment. (See <a href=\"topic.htm?path=insulinoma#H18\" class=\"medical medical_review\">&quot;Insulinoma&quot;, section on 'Treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H665809\"><span class=\"h2\">Recurrent symptoms</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Recurrent hypoglycemia after partial pancreatectomy has been observed in both NIPHS and post-gastric bypass hypoglycemia [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/5,6,39,56\" class=\"abstract_t\">5,6,39,56</a>]. In a series of 75 patients, 48 of whom responded to a questionnaire, 87 percent reported recurrence of symptoms but to a lesser degree than preoperatively [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/5\" class=\"abstract_t\">5</a>]. Despite symptom recurrence, 75 percent reported overall improvement in symptoms and quality of life. There was no difference between patients with NIPHS and post-gastric bypass hypoglycemia. Since the symptoms are usually mild when they recur, lifestyle modification or medical management may suffice. Only rarely has completion pancreatectomy been conducted [<a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/6\" class=\"abstract_t\">6</a>].</p><p class=\"headingAnchor\" id=\"H936943346\"><span class=\"h1\">SOCIETY GUIDELINE LINKS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See <a href=\"topic.htm?path=society-guideline-links-hypoglycemia-in-adults\" class=\"medical medical_society_guidelines\">&quot;Society guideline links: Hypoglycemia in adults&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Noninsulinoma pancreatogenous hypoglycemia syndrome (NIPHS) is a syndrome characterized by endogenous hyperinsulinemic hypoglycemia that is not caused by an insulinoma. Pancreatic specimens from such patients show nesidioblastosis, a term that refers to neoformation of islets of Langerhans from pancreatic duct epithelium. (See <a href=\"#H2\" class=\"local\">'Definition'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The predominant clinical feature of NIPHS is postprandial hypoglycemia and the presence of neuroglycopenic symptoms. During episodes of hypoglycemia, patients with NIPHS have biochemical findings similar to those of insulinoma, including elevated plasma insulin, C-peptide, and proinsulin concentrations; low plasma beta-hydroxybutyrate; and a negative <span class=\"nowrap\">sulfonylurea/meglitinide</span> screen (<a href=\"image.htm?imageKey=ENDO%2F56314\" class=\"graphic graphic_table graphicRef56314 \">table 1</a>). (See <a href=\"#H3\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In adults, hypoglycemia due to endogenous hyperinsulinism, with negative screens for <span class=\"nowrap\">sulfonylurea/meglitinide</span> and insulin antibodies, can be caused by a beta cell tumor (eg, insulinoma) or a functional beta cell disorder (eg, nesidioblastosis) due to either NIPHS or post-gastric bypass hypoglycemia. (See <a href=\"#H5855575\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with endogenous hyperinsulinemic hypoglycemia (and negative screens for <span class=\"nowrap\">sulfonylurea/meglitinide</span> and insulin antibodies), localization studies are necessary to distinguish between the presence of an insulinoma versus a diffuse process (islet cell <span class=\"nowrap\">hyperplasia/nesidioblastosis)</span>. Radiological localization studies are negative in patients with NIPHS and typically positive in patients with insulinoma. (See <a href=\"#H20268413\" class=\"local\">'Diagnostic evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with the clinical, biochemical, and radiological features described above, the diagnosis of NIPHS may be confirmed when pancreatic specimens from such patients show beta cell hypertrophy, islets with enlarged and hyperchromatic nuclei, and increased periductular islets by the presence of histomorphometric findings. (See <a href=\"#H20267827\" class=\"local\">'Histopathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Although nesidioblastosis following Roux-en-Y gastric bypass (RYGB) and NIPHS have some features in common (eg, postprandial hyperinsulinemic hypoglycemia, negative radiologic localization but positive calcium stimulation test, and histologic findings of nesidioblastosis), they appear to be distinct diseases.</p><p/><p class=\"bulletIndent1\">Patients with NIPHS have never undergone gastric bypass and they are predominantly male, as opposed to the female predominance for post-gastric bypass hypoglycemia. Patients with NIPHS never have insulinoma and virtually never have fasting hypoglycemia, both of which may be observed rarely in post-gastric bypass hypoglycemia. (See <a href=\"#H5855587\" class=\"local\">'Nesidioblastosis after Roux-en-Y gastric bypass surgery'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with mild to moderate symptoms due to nesidioblastosis (NIPHS or following RYGB), dietary modification (low carbohydrate diet) is a reasonable initial intervention. Those patients that are refractory to a low carbohydrate diet can be treated with an alpha-glucosidase inhibitor (eg, <a href=\"topic.htm?path=acarbose-drug-information\" class=\"drug drug_general\">acarbose</a>).</p><p/><p class=\"bulletIndent1\">For patients with persistent symptoms despite medical therapy, or for patients with severe hypoglycemia (neuroglycopenia with loss of consciousness), graded pancreatectomy is required to control symptoms. For patients with post-RYGB nesidioblastosis, conversion of the RYGB to sleeve gastrectomy is an alternative option. However, if there is no improvement, partial pancreatectomy may still be necessary. (See <a href=\"#H9\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/1\" class=\"nounderline abstract_t\">Service FJ, Natt N, Thompson GB, et al. Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes. J Clin Endocrinol Metab 1999; 84:1582.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/2\" class=\"nounderline abstract_t\">Thompson GB, Service FJ, Andrews JC, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: an update in 10 surgically treated patients. Surgery 2000; 128:937.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/3\" class=\"nounderline abstract_t\">Anlauf M, Wieben D, Perren A, et al. Persistent hyperinsulinemic hypoglycemia in 15 adults with diffuse nesidioblastosis: diagnostic criteria, incidence, and characterization of beta-cell changes. Am J Surg Pathol 2005; 29:524.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/4\" class=\"nounderline abstract_t\">Laidlaw GF. Nesidioblastoma, the islet tumor of the pancreas. Am J Pathol 1938; 2:125.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/5\" class=\"nounderline abstract_t\">Vanderveen KA, Grant CS, Thompson GB, et al. Outcomes and quality of life after partial pancreatectomy for noninsulinoma pancreatogenous hypoglycemia from diffuse islet cell disease. Surgery 2010; 148:1237.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/6\" class=\"nounderline abstract_t\">Rumilla KM, Erickson LA, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression. Mod Pathol 2009; 22:239.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/7\" class=\"nounderline abstract_t\">Kenney B, Tormey CA, Qin L, et al. Adult nesidioblastosis. Clinicopathologic correlation between pre-operative selective arterial calcium stimulation studies and post-operative pathologic findings. JOP 2008; 9:504.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/8\" class=\"nounderline abstract_t\">Won JG, Tseng HS, Yang AH, et al. Clinical features and morphological characterization of 10 patients with noninsulinoma pancreatogenous hypoglycaemia syndrome (NIPHS). Clin Endocrinol (Oxf) 2006; 65:566.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/9\" class=\"nounderline abstract_t\">Sahloul R, Yaqub N, Driscoll HK, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: quantitative and immunohistochemical analyses of islet cells for insulin, glucagon, somatostatin, and pancreatic and duodenal homeobox protein. Endocr Pract 2007; 13:187.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/10\" class=\"nounderline abstract_t\">Hong R, Choi DY, Lim SC. Hyperinsulinemic hypoglycemia due to diffuse nesidioblastosis in adults: a case report. World J Gastroenterol 2008; 14:140.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/11\" class=\"nounderline abstract_t\">Tsujino M, Sugiyama T, Nishida K, et al. Noninsulinoma pancreatogenous hypoglycemia syndrome: a rare case of adult-onset nesidioblastosis. Intern Med 2005; 44:843.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/12\" class=\"nounderline abstract_t\">Kim HK, Shong YK, Han DJ, et al. Nesidioblastosis in an adult with hyperinsulinemic hypoglycemia. Endocr J 1996; 43:163.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/13\" class=\"nounderline abstract_t\">Starke A, Saddig C, Kirch B, et al. Islet hyperplasia in adults: challenge to preoperatively diagnose non-insulinoma pancreatogenic hypoglycemia syndrome. World J Surg 2006; 30:670.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/14\" class=\"nounderline abstract_t\">McElroy MK, Lowy AM, Weidner N. Case report: focal nesidioblastosis (&quot;nesidioblastoma&quot;) in an adult. Hum Pathol 2010; 41:447.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/15\" class=\"nounderline abstract_t\">Nathan DM, Axelrod L, Proppe KH, et al. Nesidioblastosis associated with insulin-mediated hypoglycemia in an adult. Diabetes Care 1981; 4:383.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/16\" class=\"nounderline abstract_t\">McHenry C, Newell K, Chejfec G, et al. Adult nesidioblastosis. An unusual cause of fasting hypoglycemia. Am Surg 1989; 55:366.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/17\" class=\"nounderline abstract_t\">de Lonlay P, Fournet JC, Rahier J, et al. Somatic deletion of the imprinted 11p15 region in sporadic persistent hyperinsulinemic hypoglycemia of infancy is specific of focal adenomatous hyperplasia and endorses partial pancreatectomy. J Clin Invest 1997; 100:802.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/18\" class=\"nounderline abstract_t\">de Lonlay-Debeney P, Poggi-Travert F, Fournet JC, et al. Clinical features of 52 neonates with hyperinsulinism. N Engl J Med 1999; 340:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/19\" class=\"nounderline abstract_t\">Walmsley D, Matheson NA, Ewen S, et al. Nesidioblastosis in an elderly patient. Diabet Med 1995; 12:542.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/20\" class=\"nounderline abstract_t\">Tibaldi JM, Lorber D, Lomasky S, et al. Postprandial hypoglycemia in islet beta cell hyperplasia with adenomatosis of the pancreas. J Surg Oncol 1992; 50:53.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/21\" class=\"nounderline abstract_t\">Burman WJ, McDermott MT, Bornemann M. Familial hyperinsulinism presenting in adults. Arch Intern Med 1992; 152:2125.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/22\" class=\"nounderline abstract_t\">Bell DS, Grizzle WE, Dunlap NE. Nesidioblastosis causing reversal of insulin-dependent diabetes and development of hyperinsulinemic hypoglycemia. Diabetes Care 1995; 18:1379.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/23\" class=\"nounderline abstract_t\">Carlson T, Eckhauser ML, DeBaz B, et al. Nesidioblastosis in an adult: an illustrative case and collective review. Am J Gastroenterol 1987; 82:566.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/24\" class=\"nounderline abstract_t\">Raffel A, Krausch M M, Anlauf M, et al. Diffuse nesidioblastosis as a cause of hyperinsulinemic hypoglycemia in adults: a diagnostic and therapeutic challenge. Surgery 2007; 141:179.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/25\" class=\"nounderline abstract_t\">Toyomasu Y, Fukuchi M, Yoshida T, et al. Treatment of hyperinsulinemic hypoglycemia due to diffuse nesidioblastosis in adults: a case report. Am Surg 2009; 75:331.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/26\" class=\"nounderline abstract_t\">Campbell IL, Harrison LC, Ley CJ, et al. Nesidioblastosis and multifocal pancreatic islet cell hyperplasia in an adult. Clinicopathologic features and in vitro pancreatic studies. Am J Clin Pathol 1985; 84:534.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/27\" class=\"nounderline abstract_t\">Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 1-1983. A 37-year-old schizophrenic woman with hypoglycemic episode. N Engl J Med 1983; 308:30.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/28\" class=\"nounderline abstract_t\">Sandler R, Horwitz DL, Rubenstein AH, Kuzuya H. Hypoglycemia and endogenous hyperinsulinism complicating diabetes mellitus. Application of the C-peptide assay to diagnosis and therapy. Am J Med 1975; 59:730.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/29\" class=\"nounderline abstract_t\">Rayman G, Santo M, Salomon F, et al. Hyperinsulinaemic hypoglycaemia due to chlorpropamide-induced nesidioblastosis. J Clin Pathol 1984; 37:651.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/30\" class=\"nounderline abstract_t\">Farley DR, van Heerden JA, Myers JL. Adult pancreatic nesidioblastosis. Unusual presentations of a rare entity. Arch Surg 1994; 129:329.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/31\" class=\"nounderline abstract_t\">Thompson NW, Lloyd RV, Nishiyama RH, et al. MEN I pancreas: a histological and immunohistochemical study. World J Surg 1984; 8:561.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/32\" class=\"nounderline abstract_t\">Karnauchow PN. Nesidioblastosis in adults without insular hyperfunction. Am J Clin Pathol 1982; 78:511.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/33\" class=\"nounderline abstract_t\">Goudswaard WB, Houthoff HJ, Koudstaal J, Zwierstra RP. Nesidioblastosis and endocrine hyperplasia of the pancreas: a secondary phenomenon. Hum Pathol 1986; 17:46.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/34\" class=\"nounderline abstract_t\">Placzkowski KA, Vella A, Thompson GB, et al. Secular trends in the presentation and management of functioning insulinoma at the Mayo Clinic, 1987-2007. J Clin Endocrinol Metab 2009; 94:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/35\" class=\"nounderline abstract_t\">Albers N, L&ouml;hr M, Bogner U, et al. Nesidioblastosis of the pancreas in an adult with persistent hyperinsulinemic hypoglycemia. Am J Clin Pathol 1989; 91:336.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/36\" class=\"nounderline abstract_t\">Service GJ, Thompson GB, Service FJ, et al. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:249.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/37\" class=\"nounderline abstract_t\">Patti ME, McMahon G, Mun EC, et al. Severe hypoglycaemia post-gastric bypass requiring partial pancreatectomy: evidence for inappropriate insulin secretion and pancreatic islet hyperplasia. Diabetologia 2005; 48:2236.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/38\" class=\"nounderline abstract_t\">Goldfine AB, Mun E, Patti ME. Hyperinsulinemic hypoglycemia following gastric bypass surgery for obesity. Curr Opin Endocrinol Diabetes Obes 2006; 13:419.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/39\" class=\"nounderline abstract_t\">Clancy TE, Moore FD Jr, Zinner MJ. Post-gastric bypass hyperinsulinism with nesidioblastosis: subtotal or total pancreatectomy may be needed to prevent recurrent hypoglycemia. J Gastrointest Surg 2006; 10:1116.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/40\" class=\"nounderline abstract_t\">Ritz P, Hanaire H. Post-bypass hypoglycaemia: a review of current findings. Diabetes Metab 2011; 37:274.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/41\" class=\"nounderline abstract_t\">Cummings DE. Gastric bypass and nesidioblastosis--too much of a good thing for islets? N Engl J Med 2005; 353:300.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/42\" class=\"nounderline abstract_t\">Kaiser AM. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005; 353:2192.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/43\" class=\"nounderline abstract_t\">Goldfine AB, Mun EC, Devine E, et al. Patients with neuroglycopenia after gastric bypass surgery have exaggerated incretin and insulin secretory responses to a mixed meal. J Clin Endocrinol Metab 2007; 92:4678.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/44\" class=\"nounderline abstract_t\">Vella A, Service FJ. Incretin hypersecretion in post-gastric bypass hypoglycemia--primary problem or red herring? J Clin Endocrinol Metab 2007; 92:4563.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/45\" class=\"nounderline abstract_t\">Lee CJ, Brown T, Magnuson TH, et al. Hormonal response to a mixed-meal challenge after reversal of gastric bypass for hypoglycemia. J Clin Endocrinol Metab 2013; 98:E1208.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/46\" class=\"nounderline abstract_t\">McLaughlin T, Peck M, Holst J, Deacon C. Reversible hyperinsulinemic hypoglycemia after gastric bypass: a consequence of altered nutrient delivery. J Clin Endocrinol Metab 2010; 95:1851.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/47\" class=\"nounderline abstract_t\">Campos GM, Ziemelis M, Paparodis R, et al. Laparoscopic reversal of Roux-en-Y gastric bypass: technique and utility for treatment of endocrine complications. Surg Obes Relat Dis 2014; 10:36.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/48\" class=\"nounderline abstract_t\">Himpens J, Verbrugghe A, Cadi&egrave;re GB, et al. Long-term results of laparoscopic Roux-en-Y Gastric bypass: evaluation after 9 years. Obes Surg 2012; 22:1586.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/49\" class=\"nounderline abstract_t\">Doppman JL, Chang R, Fraker DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med 1995; 123:269.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/50\" class=\"nounderline abstract_t\">O'Shea D, Rohrer-Theurs AW, Lynn JA, et al. Localization of insulinomas by selective intraarterial calcium injection. J Clin Endocrinol Metab 1996; 81:1623.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/51\" class=\"nounderline abstract_t\">Kellogg TA, Bantle JP, Leslie DB, et al. Postgastric bypass hyperinsulinemic hypoglycemia syndrome: characterization and response to a modified diet. Surg Obes Relat Dis 2008; 4:492.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/52\" class=\"nounderline abstract_t\">Spanakis E, Gragnoli C. Successful medical management of status post-Roux-en-Y-gastric-bypass hyperinsulinemic hypoglycemia. Obes Surg 2009; 19:1333.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/53\" class=\"nounderline abstract_t\">Moreira RO, Moreira RB, Machado NA, et al. Post-prandial hypoglycemia after bariatric surgery: pharmacological treatment with verapamil and acarbose. Obes Surg 2008; 18:1618.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/54\" class=\"nounderline abstract_t\">Arao T, Okada Y, Hirose A, Tanaka Y. A rare case of adult-onset nesidioblastosis treated successfully with diazoxide. Endocr J 2006; 53:95.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/55\" class=\"nounderline abstract_t\">Nadelson J, Epstein A. A rare case of noninsulinoma pancreatogenous hypoglycemia syndrome. Case Rep Gastrointest Med 2012; 2012:164305.</a></li><li><a href=\"https://www.uptodate.com/contents/noninsulinoma-pancreatogenous-hypoglycemia-syndrome/abstract/56\" class=\"nounderline abstract_t\">Mathavan VK, Arregui M, Davis C, et al. Management of postgastric bypass noninsulinoma pancreatogenous hypoglycemia. Surg Endosc 2010; 24:2547.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 1782 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H12\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">DEFINITION</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">CLINICAL FEATURES</a><ul><li><a href=\"#H4\" id=\"outline-link-H4\">Symptoms</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">Biochemical findings</a></li><li><a href=\"#H20267827\" id=\"outline-link-H20267827\">Histopathology</a></li></ul></li><li><a href=\"#H5855575\" id=\"outline-link-H5855575\">DIFFERENTIAL DIAGNOSIS</a><ul><li><a href=\"#H5855581\" id=\"outline-link-H5855581\">Insulinoma</a></li><li><a href=\"#H5855587\" id=\"outline-link-H5855587\">Nesidioblastosis after Roux-en-Y gastric bypass surgery</a><ul><li><a href=\"#H666059\" id=\"outline-link-H666059\">- Dumping syndrome</a></li></ul></li></ul></li><li><a href=\"#H20268413\" id=\"outline-link-H20268413\">DIAGNOSTIC EVALUATION</a><ul><li><a href=\"#H1423373789\" id=\"outline-link-H1423373789\">Laboratory evaluation</a></li><li><a href=\"#H5854725\" id=\"outline-link-H5854725\">Localization studies</a></li></ul></li><li><a href=\"#H9\" id=\"outline-link-H9\">TREATMENT</a><ul><li><a href=\"#H10\" id=\"outline-link-H10\">Mild to moderate symptoms</a></li><li><a href=\"#H335477\" id=\"outline-link-H335477\">Severe or refractory symptoms</a></li><li><a href=\"#H665809\" id=\"outline-link-H665809\">Recurrent symptoms</a></li></ul></li><li><a href=\"#H936943346\" id=\"outline-link-H936943346\">SOCIETY GUIDELINE LINKS</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ENDO/1782|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/51119\" class=\"graphic graphic_picture\">- Nesidioblastosis light</a></li></ul></li><li><div id=\"ENDO/1782|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ENDO/56314\" class=\"graphic graphic_table\">- Interpretation laboratory tests</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=classification-epidemiology-clinical-presentation-localization-and-staging-of-pancreatic-neuroendocrine-neoplasms\" class=\"medical medical_review\">Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypoglycemia-in-adults-without-diabetes-mellitus-diagnostic-approach\" class=\"medical medical_review\">Hypoglycemia in adults without diabetes mellitus: Diagnostic approach</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hypoglycemia-in-adults-clinical-manifestations-definition-and-causes\" class=\"medical medical_review\">Hypoglycemia in adults: Clinical manifestations, definition, and causes</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=insulinoma\" class=\"medical medical_review\">Insulinoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-features-and-diagnosis-of-persistent-hyperinsulinemic-hypoglycemia-of-infancy\" class=\"medical medical_review\">Pathogenesis, clinical features, and diagnosis of persistent hyperinsulinemic hypoglycemia of infancy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=postprandial-reactive-hypoglycemia\" class=\"medical medical_review\">Postprandial (reactive) hypoglycemia</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=society-guideline-links-hypoglycemia-in-adults\" class=\"medical medical_society_guidelines\">Society guideline links: Hypoglycemia in adults</a></li></ul></div></div>","javascript":null}